Stryker Corporation

Stryker Corporation

SYK
Stryker CorporationUS flagNew York Stock Exchange
303.13
USD
-4.86
- -
116.21BMarket Cap
Stryker Corporation
SYK
(New York Stock Exchange)

Recent

price

303.13

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
18.47
21.49
22.75
23.83
25.56
26.41
30.27
33.27
36.36
39.8
38.22
45.38
48.78
54
59.3
65.71
67.49
Revenue per Share
3.21
3.48
3.41
2.66
1.36
3.82
4.4
2.73
9.5
5.57
4.26
5.29
6.23
8.34
7.86
8.49
9.74
Basic EPS, GAAP
3.44
3.13
3.8
4.47
4.09
1.89
3.81
2.57
5.45
4.12
7.43
7.26
5.38
8.26
9.15
11.21
12.28
Free Cash Flow per Basic Share
0.6
0.72
0.85
1.06
1.22
1.38
1.52
1.7
1.88
2.08
2.3
2.52
2.78
3
3.2
3.36
3.44
Dividend per Share
18.34
20.17
22.62
23.93
22.74
22.82
25.47
26.62
31.33
34.2
34.79
39.41
43.88
48.92
54.1
58.61
62.54
Book Value per Share
13.8
10.94
13.24
8.5
6.33
6.92
-0.84
-1.81
-2.66
-1.31
-13.95
-7.63
-8.32
-3.27
1.01
-6.67
-3.49
Tangible Book Value per Share
396
386
381
379
378
377
374
374
374
374
376
377
378
380
381
382
383
Basic Weighted Avg Shares
7,320
8,307
8,657
9,021
9,675
9,946
11,325
12,444
13,601
14,884
14,351
17,108
18,449
20,498
22,595
25,116
25,837
Sales/Revenue/Turnover
25.61
21.21
22.12
20.82
20.74
21.69
20.6
19.85
18.82
19.52
15.61
15.71
16.86
19.14
20.65
20.14
21.73
Operating Margin (%)
223
282
277
307
378
397
546
642
723
778
812
990
998
1,028
1,050
1,193
1,221
Depreciation Expense
1,273
1,345
1,298
1,006
515
1,439
1,647
1,020
3,553
2,083
1,599
1,994
2,358
3,165
2,993
3,246
3,729
Net Income, GAAP
26.37
20.23
23.87
17
55.6
17.06
14.26
50.56
- -
18.7
18.17
12.58
12.11
13.83
14.29
28.09
27.56
Effective Tax Rate (%)
17.39
16.19
14.99
11.15
5.32
14.47
14.54
8.2
26.12
13.99
11.14
11.66
12.78
15.44
13.25
12.92
14.43
Profit Margin (%)
6,027
5,367
6,272
5,678
4,223
4,441
4,713
4,508
4,926
6,658
4,666
5,468
3,972
4,597
7,231
6,961
7,734
Working Capital
996
1,751
1,746
2,739
3,246
3,230
6,686
6,590
8,486
10,231
13,230
12,472
11,857
10,901
12,188
14,859
14,192
LT Debt
7,174
7,683
8,597
9,047
8,595
8,511
9,550
9,980
11,730
12,807
13,084
14,877
16,616
18,593
20,634
22,420
23,988
Total Equity
18.49
15.85
14.64
14.02
7.21
14.07
13.78
7.24
- -
10.34
7.17
8.61
9.56
10.98
12.05
9.96
10.62
Return on Invested Capital (%)
17.19
15.55
13.1
9.08
4.22
11.48
11.37
6.06
- -
9.16
6.27
7.33
8.27
11.36
10.16
10.16
10.27
Return on Capital (%)
18.49
18.11
15.95
11.4
5.84
16.82
18.24
10.45
32.75
16.98
12.35
14.26
14.97
17.98
15.26
15.08
16.51
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,000
499
750
LT Borrowings
14,859
14,224
14,192
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
382
383
384
Market Capitalization
134,437
125,969
120,764

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
14,755
13,338
14,418
Cash, Cash Equivalents & STI
4,100
2,965
3,476
Accounts Receivable, Net
4,039
3,571
3,743
Inventories
5,310
5,419
5,521
Total Current Liabilities
7,794
6,315
6,684
Payables & Accruals
5,199
4,931
4,829
ST Debt
1,000
499
750
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.25%
11.39%
8.66%
Free Cash Flow
29.71%
12.11%
22.83%
Net Income, GAAP
24.03%
16.04%
8.45%
Sales/Revenue/Turnover
9.84%
11.91%
11.16%
Total Cash Common Dividend
9.46%
8.29%
5.33%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,243
5,422
5,494
6,436
22,595
2025
5,866
6,022
6,057
7,171
25,116
2026
6,020
6,589
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.07
2.17
2.19
1.43
7.86
2025
1.71
2.31
2.25
2.22
8.49
2026
1.95
3.33
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.8
0.8
0.8
0.8
3.2
2025
0.84
0.84
0.84
0.84
3.36
2026
0.88
0.88
- -
- -
- -
Business
Stryker Corporation (NYSE: SYK) develops, manufactures, and markets medical technologies, including orthopedic implants and instruments; surgical equipment and navigation systems; endoscopic and communications products; and patient handling and emergency medical equipment. The company offers its Mako robotic-arm assisted surgery platform for orthopedic procedures; Triathlon and Trident hip and knee systems; Gamma3 and T2 intramedullary nailing systems; and Ceros and Variax distal fixation systems, among other specialized devices for joint reconstruction, trauma and extremities, and spine care. Stryker provides interventional devices, including embolic products and guidewires, along with neurotechnology and spine products such as Vizor vision systems and SurgiCount safety sponges; it also delivers solutions for operating room integration and capital equipment. Founded in 1941 and headquartered in Kalamazoo, Michigan, the company operates globally across the Americas, Europe, Asia-Pacific, and other regions, serving hospitals, ambulatory surgery centers, and healthcare providers in the medtech industry. In recent developments, Stryker completed the acquisition of Artelon AB in September 2024, enhancing its sports medicine portfolio with advanced biomaterials for soft tissue regeneration. The company also acquired Wright Medical Group N.V. in 2022, bolstering its extremity reconstruction offerings, and continues to expand through strategic investments, including a new manufacturing facility in Ireland to support European growth. Additionally, Stryker launched the next-generation Mako Total Knee 2.0 application and advanced its Blue Seal bipolar sealer technology, reflecting ongoing innovation in robotics and surgical efficiency amid robust demand in orthopedics and neurotechnology segments.

Company News

  • Stryker Corporation $SYK Shares Purchased by California State Teachers Retirement System

  • Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference

  • Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money

  • Stryker Launches FDA-Cleared Apple Vision Pro Surgical App

  • Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio

  • Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center

  • Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering

  • Caisse de depot et placement du Quebec Makes New Investment in Stryker Corporation $SYK

  • Stryker Corporation $SYK Shares Sold by BNP Paribas

  • Beacon Pointe Advisors LLC Purchases Shares of 40,773 Stryker Corporation $SYK

  • PBH vs. SYK: Which Stock Is the Better Value Option?

  • 4,876 Shares in Stryker Corporation $SYK Acquired by Ancora Advisors LLC

  • Stryker to participate in the 2026 Wells Fargo Healthcare Conference

  • Do Options Traders Know Something About Stryker Stock We Don't?

  • Ally Financial Inc. Invests $4.09 Million in Stryker Corporation $SYK

  • Amazon.com (NASDAQ:AMZN) Stock Bought Rep. Thomas H. Kean, Jr.

  • Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

  • Stryker Corporation $SYK Stock Position Reduced by Bank of New York Mellon Corp

  • Advisors Preferred LLC Buys New Position in Stryker Corporation $SYK

  • B. Metzler seel. Sohn & Co. AG Makes New Investment in Stryker Corporation $SYK